# Terawulf Inc.: financial statements, quarterly

WULF · Nasdaq · CIK 1083301 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/wulf.md) · [Financials](/companies/wulf/financials.md) · [Filings](/companies/wulf/filings.md) · [Insiders](/companies/wulf/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/wulf/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [19.0](/filings/0001083301-24-000147.md) | [23.3 d](/filings/0001083301-26-000031.md) | [42.4](/filings/0001083301-25-000038.md) | [35.6](/filings/0001083301-25-000061.md) | [27.1](/filings/0001083301-25-000099.md) | [35.0 d](/filings/0001083301-26-000031.md) | [34.4](/filings/0001083301-26-000092.md) | [47.6](/filings/0001083301-26-000166.md) | [50.6](/filings/0001083301-25-000099.md) | [35.8 d](/filings/0001083301-26-000031.md) | [34.0](/filings/0001083301-26-000092.md) | [44.8](/filings/0001083301-26-000166.md) |
| Cost of revenue | $m | [8.3](/filings/0001083301-24-000147.md) | [8.9 d](/filings/0001083301-26-000031.md) | [14.4](/filings/0001083301-25-000038.md) | [13.9](/filings/0001083301-25-000061.md) | [14.7](/filings/0001083301-25-000099.md) | [19.6 d](/filings/0001083301-26-000031.md) | [24.6](/filings/0001083301-26-000092.md) | [22.1](/filings/0001083301-26-000166.md) | [17.1](/filings/0001083301-25-000099.md) | [18.9 d](/filings/0001083301-26-000031.md) | [2.4](/filings/0001083301-26-000092.md) | [12.4](/filings/0001083301-26-000166.md) |
| Gross profit | $m | [10.7](/filings/0001083301-23-000060.md) | [9.5 d](/filings/0001083301-26-000031.md) | [28.0](/filings/0001083301-24-000103.md) | [21.7](/filings/0001083301-24-000124.md) | [10.8](/filings/0001083301-25-000099.md) | [12.6 d](/filings/0001083301-26-000031.md) | [7.0](/filings/0001083301-26-000092.md) | [22.0](/filings/0001083301-26-000166.md) | [29.0](/filings/0001083301-25-000099.md) | [8.1 d](/filings/0001083301-26-000031.md) | [20.4](/filings/0001083301-26-000092.md) | [8.9](/filings/0001083301-26-000166.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [5.8](/filings/0001083301-23-000060.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(9.7)](/filings/0001083301-24-000147.md) | [(4.7) d](/filings/0001083301-26-000031.md) | [(2.3)](/filings/0001083301-25-000038.md) | [(6.8)](/filings/0001083301-25-000061.md) | [(15.7)](/filings/0001083301-25-000099.md) | [(51.4) d](/filings/0001083301-26-000031.md) | [(59.6)](/filings/0001083301-26-000092.md) | [(15.6)](/filings/0001083301-26-000166.md) | [(24.7)](/filings/0001083301-25-000099.md) | [(86.3) d](/filings/0001083301-26-000031.md) | [(162)](/filings/0001083301-26-000092.md) | [(140)](/filings/0001083301-26-000166.md) |
| Interest expense | $m | [10.3](/filings/0001083301-23-000060.md) | [9.3 d](/filings/0001083301-24-000072.md) | [11.0](/filings/0001083301-24-000103.md) | [5.3](/filings/0001083301-25-000061.md) | [0.4](/filings/0001083301-25-000099.md) | [3.0 d](/filings/0001083301-26-000031.md) | [4.0](/filings/0001083301-26-000092.md) | [4.0](/filings/0001083301-26-000166.md) | [9.8](/filings/0001083301-25-000099.md) | [62.4 d](/filings/0001083301-26-000031.md) | [67.1](/filings/0001083301-26-000092.md) | [56.4](/filings/0001083301-26-000166.md) |
| Income tax | $m | [0.0](/filings/0001083301-24-000147.md) | [0.0 d](/filings/0001083301-26-000031.md) | [0.0](/filings/0001083301-25-000038.md) | [0.0](/filings/0001083301-25-000061.md) | [0.0](/filings/0001083301-25-000099.md) | [0.0 d](/filings/0001083301-26-000031.md) | [0.0](/filings/0001083301-26-000092.md) | [0.0](/filings/0001083301-26-000166.md) | [0.0](/filings/0001083301-25-000099.md) | [0.1 d](/filings/0001083301-26-000031.md) | [0.0](/filings/0001083301-26-000092.md) | [0.0](/filings/0001083301-26-000166.md) |
| Net income | $m | [(19.1)](/filings/0001083301-24-000147.md) | [(10.5) d](/filings/0001083301-26-000031.md) | [(9.6)](/filings/0001083301-25-000038.md) | [(10.9)](/filings/0001083301-25-000061.md) | [(22.7)](/filings/0001083301-25-000099.md) | [(29.2) d](/filings/0001083301-26-000031.md) | [(61.4)](/filings/0001083301-26-000092.md) | [(18.4)](/filings/0001083301-26-000166.md) | [(455)](/filings/0001083301-25-000099.md) | [(127) d](/filings/0001083301-26-000031.md) | [(428)](/filings/0001083301-26-000092.md) | [(940)](/filings/0001083301-26-000166.md) |
| Diluted EPS | $ per share | [(0.09)](/filings/0001083301-24-000147.md) | not reported | [(0.03)](/filings/0001083301-25-000038.md) | [(0.03)](/filings/0001083301-25-000061.md) | [(0.06)](/filings/0001083301-25-000099.md) | not reported | [(0.16)](/filings/0001083301-26-000092.md) | [(0.05)](/filings/0001083301-26-000166.md) | [(1.13)](/filings/0001083301-25-000099.md) | not reported | [(1.01)](/filings/0001083301-26-000092.md) | [(1.94)](/filings/0001083301-26-000166.md) |
| Basic EPS | $ per share | [(0.09)](/filings/0001083301-24-000147.md) | not reported | [(0.03)](/filings/0001083301-25-000038.md) | [(0.03)](/filings/0001083301-25-000061.md) | [(0.06)](/filings/0001083301-25-000099.md) | not reported | [(0.16)](/filings/0001083301-26-000092.md) | [(0.05)](/filings/0001083301-26-000166.md) | [(1.13)](/filings/0001083301-25-000099.md) | not reported | [(1.01)](/filings/0001083301-26-000092.md) | [(1.94)](/filings/0001083301-26-000166.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [6.6](/filings/0001083301-23-000060.md) | [54.4](/filings/0001083301-25-000018.md) | [45.8](/filings/0001083301-24-000103.md) | [104](/filings/0001083301-24-000124.md) | [23.9](/filings/0001083301-24-000147.md) | [274](/filings/0001083301-26-000031.md) | [218](/filings/0001083301-25-000038.md) | [90.0](/filings/0001083301-25-000061.md) | [711](/filings/0001083301-25-000099.md) | [3,266](/filings/0001083301-26-000166.md) | [2,630](/filings/0001083301-26-000092.md) | [2,619](/filings/0001083301-26-000166.md) |
| Current assets | $m | [13.0](/filings/0001083301-23-000060.md) | [62.6](/filings/0001083301-25-000018.md) | [54.4](/filings/0001083301-24-000103.md) | [111](/filings/0001083301-24-000124.md) | [32.4](/filings/0001083301-24-000147.md) | [281](/filings/0001083301-26-000031.md) | [230](/filings/0001083301-25-000038.md) | [99.1](/filings/0001083301-25-000061.md) | [729](/filings/0001083301-25-000099.md) | [3,478](/filings/0001083301-26-000166.md) | [2,867](/filings/0001083301-26-000092.md) | [2,807](/filings/0001083301-26-000166.md) |
| Total assets | $m | [312](/filings/0001083301-23-000060.md) | [378](/filings/0001083301-25-000018.md) | [395](/filings/0001083301-24-000103.md) | [480](/filings/0001083301-24-000124.md) | [406](/filings/0001083301-24-000147.md) | [788](/filings/0001083301-26-000031.md) | [841](/filings/0001083301-25-000038.md) | [869](/filings/0001083301-25-000061.md) | [2,454](/filings/0001083301-25-000099.md) | [6,558](/filings/0001083301-26-000166.md) | [7,009](/filings/0001083301-26-000092.md) | [8,048](/filings/0001083301-26-000166.md) |
| Current liabilities | $m | [108](/filings/0001083301-23-000060.md) | [155](/filings/0001083301-25-000018.md) | [122](/filings/0001083301-24-000103.md) | [92.4](/filings/0001083301-24-000124.md) | [32.4](/filings/0001083301-24-000147.md) | [51.8](/filings/0001083301-26-000031.md) | [121](/filings/0001083301-25-000038.md) | [151](/filings/0001083301-25-000061.md) | [706](/filings/0001083301-25-000099.md) | [1,736](/filings/0001083301-26-000166.md) | [2,385](/filings/0001083301-26-000092.md) | [3,764](/filings/0001083301-26-000166.md) |
| Total liabilities | $m | [158](/filings/0001083301-23-000060.md) | [156](/filings/0001083301-25-000018.md) | [123](/filings/0001083301-24-000103.md) | [93.3](/filings/0001083301-24-000124.md) | [33.3](/filings/0001083301-24-000147.md) | [543](/filings/0001083301-26-000031.md) | [671](/filings/0001083301-25-000038.md) | [695](/filings/0001083301-25-000061.md) | [2,207](/filings/0001083301-25-000099.md) | [6,418](/filings/0001083301-26-000166.md) | [7,086](/filings/0001083301-26-000092.md) | [7,901](/filings/0001083301-26-000166.md) |
| Long-term debt | $m | [48.5](/filings/0001083301-23-000060.md) | [0.1](/filings/0001083301-25-000018.md) | [0.0](/filings/0001083301-24-000103.md) | [0.0](/filings/0001083301-24-000124.md) | [0.0](/filings/0001083301-24-000147.md) | [0.0](/filings/0001083301-26-000031.md) | not reported | not reported | not reported | [3,052](/filings/0001083301-26-000092.md) | [3,060](/filings/0001083301-26-000092.md) | not reported |
| Current portion of debt | $m | [76.5](/filings/0001083301-23-000060.md) | [123](/filings/0001083301-25-000018.md) | [99.4](/filings/0001083301-24-000103.md) | [72.3](/filings/0001083301-24-000124.md) | [0.0](/filings/0001083301-24-000147.md) | [0.0](/filings/0001083301-26-000031.md) | not reported | not reported | not reported | [46.3](/filings/0001083301-26-000092.md) | [43.6](/filings/0001083301-26-000092.md) | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001083301-26-000092.md) | [98.6](/filings/0001083301-26-000092.md) | not reported |
| Shareholders' equity | $m | [154](/filings/0001083301-24-000147.md) | [222](/filings/0001083301-26-000031.md) | [272](/filings/0001083301-25-000061.md) | [386](/filings/0001083301-25-000099.md) | [373](/filings/0001083301-25-000099.md) | [244](/filings/0001083301-26-000031.md) | [170](/filings/0001083301-25-000061.md) | [174](/filings/0001083301-25-000099.md) | [247](/filings/0001083301-25-000099.md) | [140](/filings/0001083301-26-000166.md) | [(78.8)](/filings/0001083301-26-000092.md) | [147](/filings/0001083301-26-000166.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [2.4 d](/filings/0001083301-24-000147.md) | [10.9 d](/filings/0001083301-26-000031.md) | [22.8](/filings/0001083301-25-000038.md) | [16.4 d](/filings/0001083301-25-000061.md) | [(20.9) d](/filings/0001083301-25-000099.md) | [(42.7) d](/filings/0001083301-26-000031.md) | [56.5](/filings/0001083301-26-000092.md) | [(54.8) d](/filings/0001083301-26-000166.md) | [(36.7) d](/filings/0001083301-25-000099.md) | [(88.2) d](/filings/0001083301-26-000031.md) | [(17.6)](/filings/0001083301-26-000092.md) | [(137) d](/filings/0001083301-26-000166.md) |
| Capital expenditure | $m | [25.4 d](/filings/0001083301-24-000147.md) | [33.8 d](/filings/0001083301-26-000031.md) | [47.0](/filings/0001083301-25-000038.md) | [46.6 d](/filings/0001083301-25-000061.md) | [20.7 d](/filings/0001083301-25-000099.md) | [154 d](/filings/0001083301-26-000031.md) | [93.7](/filings/0001083301-26-000092.md) | [120 d](/filings/0001083301-26-000166.md) | [232 d](/filings/0001083301-25-000099.md) | [615 d](/filings/0001083301-26-000031.md) | [523](/filings/0001083301-26-000092.md) | [856 d](/filings/0001083301-26-000166.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0001083301-25-000038.md) | [0.0 d](/filings/0001083301-25-000061.md) | [0.0 d](/filings/0001083301-25-000099.md) | [118 d](/filings/0001083301-26-000031.md) | [33.3](/filings/0001083301-26-000092.md) | [0.0 d](/filings/0001083301-26-000166.md) | [0.0 d](/filings/0001083301-25-000099.md) | [0.0 d](/filings/0001083301-26-000031.md) | [0.0](/filings/0001083301-26-000092.md) | [0.0 d](/filings/0001083301-26-000166.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [109](/filings/0001083301-23-000060.md) | [165](/filings/0001083301-24-000103.md) | [210](/filings/0001083301-24-000124.md) | [222](/filings/0001083301-24-000147.md) | [291](/filings/0001083301-25-000038.md) | [341](/filings/0001083301-25-000061.md) | [382](/filings/0001083301-25-000099.md) | [383](/filings/0001083301-26-000092.md) | [387](/filings/0001083301-26-000166.md) | [402](/filings/0001083301-25-000099.md) | [423](/filings/0001083301-26-000092.md) | [486](/filings/0001083301-26-000166.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 498,968,677 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001083301-26-000166.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.